137 related articles for article (PubMed ID: 22959314)
1. Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.
Lacout A; Marcy PY; El Hajjam M; Lacombe P
Med Hypotheses; 2012 Nov; 79(5):605-6. PubMed ID: 22959314
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].
Morales-Angulo C; Pérez del Molino A; Zarrabeitia R; Fernández A; Sanz-Rodríguez F; Botella LM
Acta Otorrinolaringol Esp; 2007 Apr; 58(4):129-32. PubMed ID: 17428407
[TBL] [Abstract][Full Text] [Related]
4. Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.
Flanagan BA; Collins C; Parra S
Cutis; 2012 Feb; 89(2):69-72. PubMed ID: 22474728
[TBL] [Abstract][Full Text] [Related]
5. Rendu-Osler-Weber disease: experience with 56 patients.
Sabbà C; Pasculli G; Cirulli A; Gallitelli M; Virgilio G; Guastamacchia E; Resta F; Palasciano G
Ann Ital Med Int; 2002; 17(3):173-9. PubMed ID: 12402665
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
Kanellopoulou T; Alexopoulou A
Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
[TBL] [Abstract][Full Text] [Related]
7. VEGF target in HHT lung patients: the role of bevacizumab as a possible alternative to embolization.
Lacout A; Marcy PY; Thariat J; El Hajjam M; Lacombe P
Med Hypotheses; 2012 May; 78(5):689-90. PubMed ID: 22414901
[No Abstract] [Full Text] [Related]
8. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
9. Tranexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis.
Lacout A; Marcy PY; El Hajjam M; Lacombe P
Cutis; 2013 Apr; 91(4):173-4. PubMed ID: 23763075
[No Abstract] [Full Text] [Related]
10. [Multiple pulmonary arteriovenous malformations associated with hereditary hemorrhagic telangiectasia].
Terata Y; Shioya T; Watanabe H; Sano M; Kagaya M; Watanabe A; Kashima M; Ito T; Sato K; Sasaki M; Miura M; Miura S; Sudo M; Hozumi H
Nihon Kokyuki Gakkai Zasshi; 1999 Nov; 37(11):915-21. PubMed ID: 18217315
[TBL] [Abstract][Full Text] [Related]
11. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J
Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464
[TBL] [Abstract][Full Text] [Related]
12. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
Lacout A; Marcy PY; El Hajjam M; Lacombe P
Med Hypotheses; 2013 May; 80(5):587-8. PubMed ID: 23452644
[TBL] [Abstract][Full Text] [Related]
15. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.
Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD
Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256
[TBL] [Abstract][Full Text] [Related]
16. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816
[TBL] [Abstract][Full Text] [Related]
17. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary arteriovenous malformations, hereditary hemorrhagic telangiectasia, and brain abscess.
Gallitelli M; Guastamacchia E; Resta F; Guanti G; Sabbà C
Respiration; 2006; 73(4):553-7. PubMed ID: 16043953
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience.
Mei-Zahav M; Letarte M; Faughnan ME; Abdalla SA; Cymerman U; MacLusky IB
Arch Pediatr Adolesc Med; 2006 Jun; 160(6):596-601. PubMed ID: 16754821
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous temporal abscess as a clinical manifestation of pulmonary arteriovenous malformations in a patient with hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease).
Haarmann S; Budihardja AS; Hölzle F; Wolff KD
Int J Oral Maxillofac Surg; 2007 Dec; 36(12):1211-4. PubMed ID: 17681734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
